Why the study?
Does simvastatin 80 mg/day reduce sympathetic outflow and improve vasodilation in non-hyperlipidaemic primary hypertensive subjects?
Population
14 non-hyperlipidaemic primary hypertensive subjects, mean age 58±12 years, 10 men.
Comparison
Simvastatin 80 mg/day for 4 weeks vs Placebo for 4 weeks
Design
RCT, randomised crossover, double-blind
Follow-up
4 weeks
Authors
Loading...
Supports statin consideration in normolipidemic hypertension for autonomic benefits; extends RCT evidence of pleiotropic effects beyond lipids.
Does simvastatin 80 mg/day reduce sympathetic outflow and improve vasodilation in non-hyperlipidaemic primary hypertensive subjects?
In non-hyperlipidaemic hypertensive patients, simvastatin reduces sympathetic nerve activity and improves endothelium-independent vasodilation independent of cholesterol lowering.
McGowan et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: